{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:29:02Z","timestamp":1783538942282,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T00:00:00Z","timestamp":1459555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T00:00:00Z","timestamp":1459555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Eisai Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s10637-016-0344-9","type":"journal-article","created":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T02:53:59Z","timestamp":1459565639000},"page":"329-337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of \u03b12 integrin inhibitor E7820 in patients with advanced solid tumors"],"prefix":"10.1007","volume":"34","author":[{"given":"B.","family":"Milojkovic Kerklaan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Slater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Greystoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. O.","family":"Witteveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Megui-Roelvink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Reyderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ottesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ranson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P. J.","family":"Lolkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. R. J.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,2]]},"reference":[{"key":"344_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-540-78281-0_6","volume":"180","author":"C R\u00fcegg","year":"2010","unstructured":"R\u00fcegg C, Alghisi GC (2010) Vascular integrins: therapeutic and imaging targets of tumor angiogenesis. Recent Results Cancer Res 180:83\u2013101. doi:10.1007\/978-3-540-78281-0_6","journal-title":"Recent Results Cancer Res"},{"issue":"10","key":"344_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1097\/CAD.0000000000000145","volume":"25","author":"C-C Sun","year":"2014","unstructured":"Sun C-C, Qu X-J, Gao Z-H (2014) Integrins: players in cancer progression and targets in cancer therapy. Anticancer Drugs 25(10):1107\u201321. doi:10.1097\/CAD.0000000000000145","journal-title":"Anticancer Drugs"},{"issue":"3","key":"344_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/sj.bjc.6601576","volume":"90","author":"H Jin","year":"2004","unstructured":"Jin H, Varner J (2004) Integrins: roles in cancer development and as treatment targets. Br J Cancer 90(3):561\u20135. doi:10.1038\/sj.bjc.6601576","journal-title":"Br J Cancer"},{"key":"344_CR4","unstructured":"Funahashi Y, Sugi NH, Semba T et al (2002) Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res 62(21):6116\u201323. Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12414636. Accessed October 7, 2014"},{"key":"344_CR5","doi-asserted-by":"crossref","unstructured":"Semba T, Funahashi Y, Ono N et al (2004) An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker. Clin Cancer Res 10(4):1430\u20138. Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14977846. Accessed October 7, 2014","DOI":"10.1158\/1078-0432.CCR-0109-03"},{"key":"344_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1078-0432.CCR-10-0010","volume":"17","author":"M Mita","year":"2011","unstructured":"Mita M, Kelly KR, Mita A et al (2011) Phase I study of E7820, an oral inhibitor of integrin \u03b1-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res 17:193\u2013200. doi:10.1158\/1078-0432.CCR-10-0010","journal-title":"Clin Cancer Res"},{"key":"344_CR7","doi-asserted-by":"publisher","unstructured":"Keizer RJ, Funahashi Y, Semba T et al (2011) Evaluation of \u03b12-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies. doi:10.1208\/s12248-011-9260-2","DOI":"10.1208\/s12248-011-9260-2"},{"key":"344_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10637-013-0055-4","volume":"32","author":"LA Devriese","year":"2014","unstructured":"Devriese LA, Koch KM, Mergui-Roelvink M et al (2014) Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. Invest New Drugs 32:481\u2013488. doi:10.1007\/s10637-013-0055-4","journal-title":"Invest New Drugs"},{"issue":"5","key":"344_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.eururo.2013.05.051","volume":"65","author":"M Wirth","year":"2014","unstructured":"Wirth M, Heidenreich A, Gschwend JE et al (2014) A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting \u03b1v integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. Eur Urol 65(5):897\u2013904. doi:10.1016\/j.eururo.2013.05.051","journal-title":"Eur Urol"},{"issue":"11","key":"344_CR10","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/sj.bjc.6603171","volume":"94","author":"ME Cianfrocca","year":"2006","unstructured":"Cianfrocca ME, Kimmel KA, Gallo J et al (2006) Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 94(11):1621\u20136. doi:10.1038\/sj.bjc.6603171","journal-title":"Br J Cancer"},{"issue":"3","key":"344_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/bjc.2011.183","volume":"105","author":"S O\u2019Day","year":"2011","unstructured":"O\u2019Day S, Pavlick A, Loquai C et al (2011) A randomised, phase II study of intetumumab, an anti-\u03b1v-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 105(3):346\u201352. doi:10.1038\/bjc.2011.183","journal-title":"Br J Cancer"},{"issue":"1","key":"344_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/annonc\/mds281","volume":"24","author":"B Besse","year":"2013","unstructured":"Besse B, Tsao LC, Chao DT et al (2013) Phase Ib safety and pharmacokinetic study of volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 24(1):90\u20136. doi:10.1093\/annonc\/mds281","journal-title":"Ann Oncol"},{"key":"344_CR13","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2009.26.6650","volume":"28","author":"R Stupp","year":"2010","unstructured":"Stupp R, Hegi ME, Neyns B et al (2010) Phase I\/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28:2712\u20132718. doi:10.1200\/JCO.2009.26.6650","journal-title":"J Clin Oncol"},{"issue":"10","key":"344_CR14","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","volume":"15","author":"R Stupp","year":"2014","unstructured":"Stupp R, Hegi ME, Gorlia T et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071\u201322072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1100\u20138. doi:10.1016\/S1470-2045(14)70379-1","journal-title":"Lancet Oncol"},{"issue":"3","key":"344_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/annonc\/mdu003","volume":"25","author":"JB Vermorken","year":"2014","unstructured":"Vermorken JB, Peyrade F, Krauss J et al (2014) Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent\/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I\/II ADVANTAGE trial (phase II part). Ann Oncol 25(3):682\u20138. doi:10.1093\/annonc\/mdu003","journal-title":"Ann Oncol"},{"issue":"1078\u20130432 (Prin","key":"344_CR16","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/1078-0432.CCR-12-1707","volume":"19","author":"DA Reardon","year":"2013","unstructured":"Reardon DA, Groves MD, Wen PY et al (2013) A phase I\/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res 19(1078\u20130432 (Print)):900\u2013908","journal-title":"Clin Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0344-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-016-0344-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0344-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0344-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:54:29Z","timestamp":1678510469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-016-0344-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,2]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["344"],"URL":"https:\/\/doi.org\/10.1007\/s10637-016-0344-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,2]]},"assertion":[{"value":"17 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work was supported by Eisai Inc.L.Reyderman and L.Ottesen are employed by Eisai. Other authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}